Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Sep 16, 2023; 11(26): 6105-6121
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6105
Table 1 Antibodies candidate against severe acute respiratory syndrome coronavirus 2 under investigation by pharmaceutical companies
Antibody
Mechanism
Company
Stage of study/identification method
Canakinumab (ilaris®)IL-1β inhibitorNovartisIn clinical stage for several inflammatory diseases including arthritis, periodic fever and lung cancer; repurposed by novartis for COVID-19
Secukinumab (cosentyx®)IL-17 inhibitorNovartisIn clinical stage for several autoimmune diseases including psoriasis; repurpose by novartis for COVID-19
TZLS-501Fully human monoclonal antibody targeting the receptor of IL-6, it binds to both membrane-bound and soluble forms of IL-6R, and rapidly depletes the circulating levels of IL-6 in bloodTiziana Life Sciences and NovimmunePreclinical stage
PritumumabFully human IgG antibody targeting vimentinNascent Biotech Inc.Received FDA approve for several carcinoma; Research began for COVID-19
COVID-HIG and COVID-EIGHyperimmune polyclonal antibody derived from human plasma or immunized horseEmergent BioSolutionsEnter clinical trial within 4-5mo
RcigRecombinant anti SARS-CoV-2 hyperimmune gamma globulin, polyclonal antibodiesGigaGenPreclinical stage-Aimed for COVID19 hospitalized patients and prophylaxis in high-risk individuals
Antibody cocktail including REGN3048-3051Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patientsRegeneronPhase 1 clinical trial for Middle East Respiratory Syndrome completed last year; clinical trial for SARS-CoV-2 starts by early summer